Mussaenda macrophylla Wall. exhibit anticancer activity against Dalton’s lymphoma ascites (DLA) bearing mice via alterations of redox-homeostasis and apoptotic genes expression

The Journal of Basic and Applied Zoology

Table 2 Effect of MMAE and DOX treatment on DLA bearing mice on the tumor response assessment based on MST, AST, % IMLS, % IALS and T/C ratio

Dose (mg/kg b.wt)	MST	AST	% IMLS	% IALS	% T/C ratio
DLA Control	15.0 ± 1.57	15.2 ± 1.46	–	–	–
DLA + MMAE₅₀	21.0 ± 1.50**	21.3 ± 1.34**	40.0 ± 1.57^b	40.7 ± 2.35^b	140.0 ± 2.57^⋆
DLA + MMAE₁₀₀	29.5 ± 1.28***	27.3 ± 1.91***	96.6 ± 1.88^c	80.1 ± 1.96^c	196.6 ± 3.33^⋆
DLA + MMAE₁₅₀	24.0 ± 1.52***	22.5 ± 1.04**	60.0 ± 2.00^a	46.4 ± 2.56^b	160.0 ± 2.80^⋆
DLA + DOX_0.5	22.5 ± 1.50**	24.2 ± 1.56***	63.3 ± 2.35^a	59.4 ± 1.86^a	163.3 ± 2.48^⋆

DLA Control: DLA bearing mice without treatment; DLA + MMAE_50, DLA + MMAE_100, DLA + MMAE₁₅₀: DLA bearing mice treated with aqueous extract of M. macrophylla at the dose of 50, 100 and 150 mg/kg, respectively. DOX_0.5: DLA bearing mice treated with doxorubicin (0.5 mg/kg). The results were expressed as percent (%) ± SEM, n = 10
**p ≤ 0.01; ***p ≤ 0.001between the control and treatment groups
Different letters indicates significant variation between different treatment groups
^⋆ T/C ratio > 120